Clinical analysis not only confirms the tumor suppressive role of RIP3 methylation and PRMT1, but also suggests that RIP3ADMA and PRMT1 can be the molecular markers for evaluating the colon adenocarcinoma malignancy. Here, PRMT1 is linked to colon adenocarcinoma.